Merck today announced recipients of the fourth annual Grant for Oncology Innovation (GOI) awards. The three winners of this prestigious program were awarded €1 million in total to progress their research.
Recipients of the 2017 GOI award are:
- Renata Maria Grifantini, National Institute of Molecular Genetics, Milan, Italy, for her proposal: “Novel targets of tumor-infiltrating CD4+ regulatory T-cells for immunotherapy”
- Alena Gros Vidal, Vall d’Hebron Institute of Oncology, Vall d’Hebron Hospital, Barcelona, Spain, for her proposal: “Personalized non-invasive T-cell therapies targeting the mutanome”
- Anguraj Sadanandam and Naureen Starling, Institute of Cancer Research, London and Royal Marsden Hospital, London, UK, for their proposal: “Characterizing the evolution of metastatic colorectal cancer (mCRC) and its immune microenvironment for therapeutic vulnerability”
Chosen from a total of 100 applicants worldwide, and judged by a fully independent scientific steering committee of internationally renowned oncology experts, the winning proposals were selected based on relevance to patient care, innovative approach, scientific impact, feasibility and relevance for the personalization of treatment.
